Friday, September 4, 2026

Clinical Trial News: July-August 2026

FDA Drug Approvals

07-Jul-2026: Trutakna (atacicept-vmjy)
FDA approved Trutakna to reduce proteinuria in adults with primary IgA nephropathy. FDA
13-Jul-2026: Leqembi (lecanemab)
FDA approved the first at-home starting dose option for Alzheimer's disease treatment, potentially reducing the burden of initiating therapy in an infusion setting. FDA
16-Jul-2026: Lipfendra (enlicitide)
Approved as the first oral PCSK9 inhibitor for lowering LDL cholesterol. FDA
19-Aug-2026: Pasatru (garetosmab-grts)
Approved as the second treatment for fibrodysplasia ossificans progressiva, a rare disorder involving abnormal bone formation. FDA
25-Aug-2026: Imaavy (nipocalimab-aahu)
Approved as the first drug for warm autoimmune hemolytic anemia. FDA
26-Aug-2026: Rasonque (daraxonrasib)
Approved as a first-in-class RAS inhibitor for metastatic pancreatic cancer. FDA
27-Aug-2026: Lisraya (brepocitinib)
Approved as the first oral drug specifically indicated for adult dermatomyositis. FDA
28-Aug-2026: Mimrylo (rusfertide)
Approved as the first drug of its kind for adults with polycythemia vera. FDA
31-Aug-2026: Besremi (ropeginterferon alfa-2b-njft)
FDA approved Besremi for essential thrombocythemia. FDA
06-Aug-2026: Tudriqev (vusolimogene oderparepvec-wtpg)
Accelerated approval granted for this engineered oncolytic viral immunotherapy in combination with nivolumab for treatment-resistant advanced melanoma. FDA

FDA takeaway: July and August featured several first-in-class or highly differentiated therapies across oncology, rare disease, immunology, cardiovascular disease and CNS. FDA 2026 Novel Drug Approvals

Regulatory Updates

United States: FDA

16-Jul-2026: Oncology trial eligibility guidance
FDA finalized recommendations addressing laboratory values, performance status, and washout periods in cancer trials. The goal is to reduce unnecessarily restrictive eligibility criteria and improve patient access.
18-Aug-2026: Generative AI regulation
FDA requested public feedback on its regulatory approach for generative-AI-enabled medical devices. FDA
25-Aug-2026: Digital health
FDA authorized the first wearable device capable of continuously monitoring both glucose and ketones. FDA

European Union: EMA

23-Jul-2026: CHMP recommendations
EMA's CHMP recommended 12 medicines for approval, including treatments for oncology, cardiovascular disease, dermatology and rare disease. EMA
Jul-Aug 2026: CTIS modernization
EMA continued work on simplifying Clinical Trial Information System processes and improving safety reporting. EMA

United Kingdom: MHRA

17-Aug-2026: Phase 1 14-Day Pilot
MHRA published its pilot program to reduce the first regulatory assessment cycle for qualifying Phase 1 healthy-volunteer trials toward 14 calendar days. MHRA

Canada: Health Canada

29-Jul-2026: Clinical trial transparency
Updated guidance strengthened requirements and expectations around registration and public disclosure of clinical-trial information. Health Canada
15-Jul-2026: Regulatory reliance
Health Canada introduced a framework allowing greater use of trusted foreign regulatory assessments to reduce duplication and speed access. Health Canada

Australia: TGA

03-Aug-2026: TAVNEOS review
TGA began reviewing avacopan after concerns were raised about the integrity and reliability of supporting clinical-trial data. TGA

China: NMPA

20-Aug-2026: AI + drug regulation
NMPA released implementation guidance covering the use of AI in drug review, inspection, testing and surveillance. NMPA

Key Trial Results

23-Jul-2026: Povorcitinib in hidradenitis suppurativa
The Phase 3 STOP-HS1 and STOP-HS2 trials were published in Nature Medicine, supporting continued development of povorcitinib for moderate-to-severe hidradenitis suppurativa. Nature Medicine
17-Aug-2026: Enhertu in HER2-mutant NSCLC
DESTINY-Lung04 met its primary endpoint, showing statistically significant and clinically meaningful improvement in progression-free survival in the first-line setting. AstraZeneca
19-Aug-2026: Intismeran autogene
Merck and Moderna reported positive Phase 3 INTerpath-001 results. The personalized mRNA cancer vaccine plus Keytruda improved recurrence-free and distant metastasis-free survival in resected melanoma. Merck
29-Aug-2026: TNX-103 follow-up data
Additional Phase 3 LEVEL results showed biologic activity in a lower-function subgroup, including improvement in six-minute walk distance and reductions in NT-proBNP. Tenax

Why it matters: Personalized cancer vaccines and targeted therapies are moving closer to routine clinical development, while obesity and oncology continue to generate some of the largest potential commercial opportunities.

Clinical Trial Setbacks

09-Jul-2026: Wainua
AstraZeneca and Ionis reported that the Phase 3 CARDIO-TTRansform trial failed to meet its primary composite cardiovascular endpoint in ATTR-CM. AstraZeneca
10-Aug-2026: TNX-103
Tenax reported that the Phase 3 LEVEL study did not meet its primary endpoint of improving six-minute walk distance. Tenax
Jul-2026: EPCORE DLBCL-1
AbbVie and Genmab clarified that overall survival was the sole U.S. primary endpoint and that it was not met. AbbVie

The lesson: Strong biomarkers, biological rationale and encouraging subgroups do not guarantee a successful registrational endpoint.

Technological Breakthroughs

19-Aug-2026: Robotic blood draws
FDA authorized Aletta, the first standalone robotic blood-draw device. FDA
25-Aug-2026: Continuous monitoring
FDA authorized a wearable capable of continuously monitoring glucose and ketones. FDA
Jul-Aug 2026: Digital endpoints
FDA continued work on digitally derived measures from wearables, sensors and other technologies.
19-Aug-2026: Personalized manufacturing
Positive Phase 3 cancer-vaccine data highlights the potential of individualized treatment manufacturing, but also adds significant operational and supply-chain complexity.

AI Latest News

18-Aug-2026: FDA and GenAI
FDA launched a public discussion on the regulation of generative-AI-enabled medical devices. FDA
10-Aug-2026: Novo Nordisk + AWS
Novo Nordisk selected AWS as a strategic AI and cloud partner to accelerate drug discovery and modernize R&D. A new London co-innovation hub will combine AI specialists with Novo Nordisk research teams. Novo Nordisk
Aug-2026: AI and clinical development
Pharmaceutical companies continued expanding AI into study design, document generation, data analysis and regulatory workflows.
2026: Real-world AI evidence
Emerging research increasingly shows that model accuracy alone is not enough. Adoption depends on whether AI actually improves workflow, decisions and outcomes.

The big AI lesson: The winning applications won't necessarily be the ones generating the most content. They'll be the ones that remove unnecessary work or improve a decision.

M&A Deals

06-Jul-2026: Vertex acquires Crinetics
Approximately $10 billion. Adds Palsonify and a late-stage endocrine pipeline. Vertex
06-Jul-2026: Novartis acquires Myricx Bio
Up to $1.5 billion, including $1.1 billion upfront. Focused on next-generation ADC payload technology. Novartis
16-Jul-2026: Lilly acquires AtaiBeckley
Approximately $2.8 billion upfront plus up to $1 billion in milestones, expanding Lilly's neuroscience pipeline. Lilly
03-Aug-2026: Curium and Lantheus
Transaction valued at up to $8 billion, combining radiopharmaceutical diagnostics and therapeutics. Curium
31-Aug-2026: Lilly acquires Merida Biosciences
Up to $2.875 billion, expanding Lilly's autoimmune and allergy pipeline. Reuters

M&A takeaway: Big Pharma continues buying differentiated platforms, late-stage assets and technologies that can fill future pipeline gaps.

Market Insights

Jul-Aug 2026: Biotech capital markets strengthen
IPO activity continued to improve compared with 2025, giving clinical-stage companies additional access to capital.
Jul-Aug 2026: M&A remains strong
Oncology, immunology, CNS, radiopharmaceuticals and rare disease remained major areas for deal activity.
Aug-2026: Investors remain selective
Strong clinical evidence and differentiated platforms continue to attract capital, while earlier-stage companies face greater scrutiny.
2026: Patent-cliff pressure continues
Large pharmaceutical companies are increasingly using M&A and licensing to replace future revenue threatened by loss of exclusivity.

Pipeline: Q4 2026 & 2027

27-Nov-2026: BBP-418, BridgeBio
FDA PDUFA date for limb-girdle muscular dystrophy R9.
28-Nov-2026: D-PLEX100, PolyPid
FDA PDUFA date for prevention of surgical-site infections.
12-Dec-2026: Imsidolimab, Vanda
FDA PDUFA date for generalized pustular psoriasis.
Q1 2027: Retatrutide, Eli Lilly
Planned BLA submission for obesity following Phase 3 development.
14-Apr-2027: Ozekibart, Inhibrx
FDA PDUFA date for conventional chondrosarcoma.
28-Apr-2027: Varegacestat, Immunome
FDA PDUFA date for desmoid tumors.
08-May-2027: Encaleret, BridgeBio
FDA PDUFA date for autosomal dominant hypocalcemia.
Q1 2027: OPERA-01, Olema
Expected Phase 3 topline results in breast cancer.
2H 2027: Bel-sar, Aura Biosciences
Expected Phase 3 topline results in ocular oncology.

Summary

Date	Category	Company / Drug	Key Development
07-Jul-2026	FDA Approval	Trutakna	IgA nephropathy
16-Jul-2026	FDA Approval	Lipfendra	First oral PCSK9 inhibitor
17-Aug-2026	Regulatory	MHRA	Phase 1 14-day pilot
19-Aug-2026	Trial Result	Intismeran autogene	Positive Phase 3 melanoma results
19-Aug-2026	Technology	Aletta	First robotic blood-draw device
25-Aug-2026	Technology	Glucose/ketone wearable	First continuous dual monitoring device
26-Aug-2026	FDA Approval	Rasonque	First-in-class targeted pancreatic cancer therapy
28-Aug-2026	FDA Approval	Mimrylo	First drug of its kind for polycythemia vera
03-Aug-2026	M&A	Curium / Lantheus	Up to $8B
31-Aug-2026	M&A	Lilly / Merida	Up to $2.875B
Q4 2026	Pipeline	Multiple assets	Several major PDUFA dates
2027	Pipeline	Retatrutide + others	Major obesity, oncology and rare-disease catalysts

The Big Picture

Obesity: The next generation is moving beyond traditional GLP-1 therapy toward multi-agonists and oral treatments.
Oncology: Personalized vaccines, ADCs, targeted therapies and immunotherapies continue driving innovation.
Regulation: FDA, EMA, MHRA and other agencies are working to reduce unnecessary trial friction while increasing evidence expectations.
AI: The focus is shifting from AI that generates content to AI that improves clinical and operational decisions.
M&A: Big Pharma continues using acquisitions and licensing to rebuild pipelines before upcoming patent losses.
2027: Expect heavy activity across obesity, oncology, CNS and rare disease.

Quick Links

2026 Clinical Trials Dashboard
M&A Tracker: Intellitrials M&A Tracker
FDA Approvals: Intellitrials FDA Approvals

Saturday, August 8, 2026

ClinicalTrials.gov Dashboard

See the latest in Industry-Sponsored Clinical Trials

Clinical Trials Dashboard

Saturday, June 6, 2026

Clinical Trial News 06-Jun-2026

FDA Drug Approvals

Xocova (ensitrelvir): Approved in early June as the first oral antiviral for post-exposure prevention of COVID-19 in adults and adolescents. The treatment is designed for people who have been exposed to the virus but are not yet showing symptoms. Developed by Shionogi. FDA coverage: https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026

Zaynich (cefepime-zidebactam): Received FDA approval for the treatment of complicated urinary tract infections caused by certain drug-resistant bacteria. The novel mechanism is expected to help address growing antimicrobial resistance concerns. Developed by Wockhardt. More information: https://m.economictimes.com/industry/healthcare/biotech/pharmaceuticals/fda-approval-puts-wockhardts-zaynich-in-9-billion-antibiotics-market/articleshow/131429108.cms

Loargys (pegzilarginase-nbln): Recently added to the FDA's 2026 list of novel drug approvals for the treatment of Arginase 1 Deficiency, a rare inherited metabolic disorder affecting children and adults. FDA announcement: https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026

FDA Cell & Gene Therapy Guidance: The FDA released draft guidance aimed at speeding development of gene and cell therapies by allowing sponsors to leverage existing scientific evidence instead of duplicating studies. The move could shorten development timelines for rare disease programs.

M&A Deals

AI Drug Discovery Investment Stays Strong: Funding continues flowing into AI-driven biotech companies as investors look for platforms that can improve target identification and drug design. Large pharmaceutical companies remain active partners and investors.

Patent Cliff Keeps Driving Deals: Major pharmaceutical companies continue to pursue acquisitions and licensing agreements as billions of dollars in branded drug revenue approach loss of exclusivity over the next several years.

Biotech Capital Markets Improve: IPO and financing activity has gradually strengthened during the first half of 2026, particularly for companies working in obesity, oncology, and AI-enabled drug discovery.

Clinical Trial Setbacks

Cingulate ADHD Drug Receives Complete Response Letter: The FDA declined to approve CTx-1301 for ADHD, citing manufacturing issues rather than concerns about safety or effectiveness. The company plans to address the deficiencies and resubmit.

Gene Therapy Programs Face Ongoing Challenges: While regulators are working to streamline development, many companies continue to face hurdles around trial design, endpoint selection, and manufacturing consistency.

Biotech Layoffs Continue: Cost-cutting remains a theme across the sector as companies prioritize late-stage assets and conserve cash while financing conditions remain selective.

Technological Breakthroughs

FDA Pushes Faster Gene Therapy Development: New draft guidance encourages developers to build on existing scientific knowledge, potentially reducing unnecessary animal studies and duplicate testing.

AI Continues Moving Into Drug Development: Drug companies are increasingly using generative AI to help design molecules, summarize clinical data, and prepare regulatory documents. The technology is becoming a practical tool rather than just a research experiment.

Adaptive Trial Designs Gain Momentum: More sponsors are using flexible study designs that allow modifications during a trial based on accumulating data. These approaches are becoming especially common in oncology and rare disease research.

Market Insights

Antimicrobial Resistance Returns to the Spotlight: The approval of new antibiotics like Zaynich highlights renewed investment in infectious disease research after years of limited innovation.

Rare Disease Remains a Growth Area: FDA support for gene therapies and treatments for ultra-rare conditions continues to attract investment despite broader market uncertainty.

Regulatory Modernization Continues: The FDA is increasingly focused on faster reviews, smarter use of existing evidence, and technology-driven oversight to help move promising therapies to patients more quickly.

Summary Table: Major FDA Actions in June 2026

Brand Name	Active Ingredient	Company	Indication	Month
Xocova	Ensitrelvir	Shionogi	Post-Exposure COVID-19 Prevention	Jun 2026
Zaynich	Cefepime + Zidebactam	Wockhardt	Complicated Urinary Tract Infection (cUTI)	Jun 2026
Loargys	Pegzilarginase-nbln	Immedica	Arginase 1 Deficiency	Jun 2026

Sources

FDA Novel Drug Approvals: https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026

FDA Gene Therapy Guidance: https://www.reuters.com/legal/litigation/us-fda-proposes-using-existing-science-speed-up-gene-therapy-development-2026-06-02/

Xocova Approval: https://www.pharmexec.com/view/fda-approves-xocova-first-oral-post-exposure-covid-19-prevention

Zaynich Approval:
https://m.economictimes.com/industry/healthcare/biotech/pharmaceuticals/fda-approval-puts-wockhardts-zaynich-in-9-billion-antibiotics-market/articleshow/131429108.cms

Cingulate Complete Response Letter: https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-declines-approve-cingulates-adhd-drug-2026-06-02/

Friday, May 15, 2026

Clinical Trial News 15-May-2026

FDA Drug Approvals

Veppanu (vepdegestrant): Approved 01-May-2026 for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer following endocrine therapy. Developed by Arvinas.

Bizengri (zenocutuzumab-zbco): Approved 08-May-2026 for advanced or metastatic cholangiocarcinoma with NRG1 gene fusion after prior systemic therapy. Partner Therapeutics.

Beqalzi (sonrotoclax): Accelerated approval granted 13-May-2026 for relapsed or refractory mantle cell lymphoma after at least two prior therapies including a BTK inhibitor. BeOne Medicines.

Inqovi + Venetoclax Combination: Approved 13-May-2026 for newly diagnosed acute myeloid leukemia in older adults or those unable to undergo intensive induction chemotherapy. Taiho Oncology.

FDA Real-Time Clinical Trials Pilot: FDA launched a new initiative enabling regulators to monitor aggregated clinical trial data in near real time, aiming to reduce development timelines and administrative delays.

M&A Deals

Isomorphic Labs Funding Round: AI drug discovery company Isomorphic Labs raised $2.1 billion to scale AI-powered drug design platforms and accelerate movement toward first human trials. Backed by Alphabet, GV, and Thrive Capital.

Biopharma M&A Surge Continues: Q1 2026 biotech deal value reached approximately $84 billion, nearly double the same period last year, driven by looming patent expirations and pipeline gaps across major pharma companies.

Generate Biomedicines IPO Push: Generate Biomedicines filed for a U.S. IPO targeting a valuation of roughly $2.2 billion, highlighting investor appetite for AI-native biotech firms.

Clinical Trial Setbacks

Replimune RP1 Rejection: FDA again rejected Replimune’s melanoma therapy RP1 after determining the company failed to sufficiently address concerns related to clinical trial data and study interpretation.

Regenxbio RGX-121 CRL Fallout: Regenxbio received an FDA rejection for its Hunter syndrome gene therapy RGX-121, citing concerns over trial design, endpoints, and use of natural history controls.

Regulatory Uncertainty at FDA: The unexpected resignation of FDA Commissioner Marty Makary introduced concerns around regulatory consistency, leadership stability, and review timelines across biotech.

Technological Breakthroughs

FDA Real-Time Clinical Trials Initiative: The FDA’s new pilot program allows continuous review of aggregated clinical trial data rather than waiting for traditional milestone submissions. Companies including Johnson & Johnson, AstraZeneca, and Amgen are participating.

AI-Powered IND Acceleration: Sponsors increasingly report dramatic reductions in regulatory document preparation time through generative AI systems. FDA and industry leaders are moving toward AI-assisted submission review and automated signal detection.

Bayesian Trial Designs Gain Momentum: FDA’s 2026 draft guidance on Bayesian methodologies is pushing broader adoption of adaptive and platform trial models, especially in rare disease and oncology development.

Market Insights

Patent Cliff Pressure Intensifies: Analysts estimate more than $300 billion in branded drug revenue is vulnerable to loss of exclusivity over the next five years, fueling aggressive acquisition activity across oncology, immunology, obesity, and rare disease biotech.

AI Biotech Still Faces Skepticism: While investment into AI drug discovery continues exploding, many researchers and biotech professionals remain cautious about claims that AI alone can improve clinical success rates without stronger biological datasets and wet lab validation.

Regulatory Modernization Accelerates: FDA’s broader modernization push now includes AI integration, faster inspections, real-time trial oversight, and expanded use of adaptive evidence generation models.

Summary: Major FDA Actions — May 2026

Brand Name	Active Ingredient	Company	Indication	Approval Date
Veppanu	Vepdegestrant	Arvinas	ER+/HER2- Metastatic Breast Cancer	01-May-2026
Bizengri	Zenocutuzumab-zbco	Partner Therapeutics	NRG1+ Cholangiocarcinoma	08-May-2026
Beqalzi	Sonrotoclax	BeOne Medicines	Relapsed/Refractory Mantle Cell Lymphoma	13-May-2026
Inqovi + Venetoclax	Decitabine/Cedazuridine + Venetoclax	Taiho Oncology	Newly Diagnosed AML	13-May-2026

Quick Links

2026 Clinical Trials Dashboard: Clinical Trials Dashboard
M&A Tracker: lebolger.github.io/Intellitrials/docs/mnatracker.html
FDA Approvals: https://lebolger.github.io/Intellitrials/fda-approvals.html

Tuesday, April 14, 2026

Clinical Trial News 14-Apr-2026

Clinical Trials Monthly: April 2026

FDA Approvals

The U.S. Food and Drug Administration (FDA) remained active in April, with several notable approvals and label expansions.

Alzheimer’s therapy expansion: The FDA expanded labeling for an anti-amyloid therapy to include earlier-stage patients, continuing its cautious support of this drug class.
Rare disease gene therapy: A one-time gene therapy for a pediatric neuromuscular disorder received approval, reflecting continued momentum in high-impact rare disease treatments.

Sources:
https://www.fda.gov/news-events/press-announcements
https://www.fda.gov/drugs/news-events-human-drugs

M&A Deals

Biotech dealmaking showed signs of recovery, with a focus on strategic and lower-risk structures.

Oncology acquisition: A large pharmaceutical company acquired a clinical-stage oncology biotech in a multi-billion dollar deal centered on a Phase II asset.
AI-driven partnerships: Companies increasingly pursued partnerships with milestone-based structures rather than full acquisitions.

Sources:
https://www.reuters.com/markets/deals/
https://www.bloomberg.com/markets

Clinical Trial Successes & Setbacks

Successes

Obesity and metabolic disease: A Phase III GLP-1 combination therapy demonstrated significant weight loss and metabolic improvements.
Oncology: A targeted therapy met its primary endpoint, improving progression-free survival in a biomarker-defined population.

Setbacks

Alzheimer’s disease: A late-stage trial targeting a novel pathway failed to meet endpoints, highlighting ongoing challenges in CNS drug development.
Immunology safety concerns: A trial was partially placed on hold due to adverse events.

Sources:
https://www.nejm.org/
https://www.thelancet.com/
https://www.statnews.com/
https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts

Tech Breakthroughs

Decentralized trials: Hybrid trial models continue to expand, improving patient access and enrollment timelines.
Digital endpoints: Wearables and digital biomarkers are gaining regulatory acceptance for use in clinical trials.

Sources:
https://www.mckinsey.com/industries/life-sciences
https://www.nature.com/

AI Developments

Protocol optimization: AI tools are being used to simulate trial designs and reduce amendments.
Patient recruitment: Machine learning models are improving patient matching and site selection.
Regulatory engagement: The FDA continues to explore frameworks for AI use in drug development.

Sources:
https://www.technologyreview.com/
https://www.deloitte.com/
https://www.fda.gov/science-research/artificial-intelligence

Market Insights

Funding: Biotech venture funding showed modest recovery following prior downturns.
IPO activity: The IPO market reopened cautiously, with stable but not high-performing entries.
Pipeline focus: Continued investment in obesity, oncology, and CNS therapies.

Sources:
https://www.wsj.com/finance
https://www.reuters.com/markets

Summary

FDA continues active approvals with increased scrutiny
M&A activity returning with more disciplined deal structures
Strong performance in metabolic disease; continued challenges in Alzheimer’s
Incremental progress in decentralized trials and digital endpoints
AI adoption expanding in trial design and execution
Market conditions stabilizing with cautious optimism

Friday, March 13, 2026

Clinical Trial News: 13-Mar-2026

Here's your full roundup of what's been moving in clinical trials, FDA decisions, M&A, and policy.

FDA Drug Approvals

Keytruda / Keytruda Qlex (pembrolizumab) — Ovarian Cancer: The biggest oncology approval of the period. The FDA approved Keytruda and Keytruda Qlex in combination with paclitaxel, with or without bevacizumab, for adults with PD-L1+ platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma who have received one or two prior treatment regimens. Based on the Phase 3 KEYNOTE-B96 trial, the regimen reduced the risk of disease progression or death by 28% and the risk of death by 24% vs. placebo. This is the first PD-1 inhibitor ever approved for this population — a population that historically had almost nothing after platinum failure. A big moment for the field. FDA Link | Merck Press Release

Adquey (difamilast 1% ointment): Approved February 12, 2026 for mild-to-moderate atopic dermatitis in adults and pediatric patients aged 2 and older. A novel non-steroidal topical PDE4 inhibitor from Acrotech Biopharma and Otsuka — the third PDE4 inhibitor in this class, joining crisaborole and roflumilast. No application-site stinging issue that plagued earlier entrants, and a strong Phase III IGA success rate. FDA Approval Letter | Acrotech Press Release

Filkri (filgrastim-laha): Approved February 17, 2026 as a biosimilar to Neupogen for neutropenia across multiple oncology and radiation settings. Accord BioPharma's sixth biosimilar approval — part of a stated push to build one of the deepest biosimilar portfolios in the industry. More competition, more access, lower costs. The biosimilar engine keeps running. Accord BioPharma Press Release

Bysanti (milsaperidone): Approved February 20, 2026 for acute bipolar I disorder and schizophrenia in adults. Vanda Pharmaceuticals' new chemical entity that rapidly interconverts to iloperidone — a pharmacokinetic bridging strategy that allowed the FDA review to leverage 100,000+ patient-years of iloperidone real-world data. Commercial availability expected Q3 2026, with a Phase 3 MDD adjunctive study reading out by year-end. Vanda Press Release

Loargys (pegzilarginase-nbln): FDA granted accelerated approval February 23, 2026 to Immedica Pharma's enzyme replacement therapy for hyperargininemia in patients aged 2 and older with Arginase 1 Deficiency — an ultra-rare metabolic disorder affecting only an estimated 250 patients in the U.S. First and only therapy proven to lower plasma arginine. Expected to be commercially available in April 2026. FDA Approval Letter | Immedica Press Release

Desmoda (desmopressin acetate oral solution): Approved February 25, 2026 for central diabetes insipidus across all ages. A new formulation of a well-established molecule — important for patients who can't use intranasal or injectable routes. Source

Summary Table: Recent FDA Actions (Feb 12 – Mar 13, 2026)

Brand Name	Active Ingredient	Company	Indication	Approval Date
Keytruda / Keytruda Qlex	Pembrolizumab	Merck	Platinum-Resistant Ovarian Cancer (PD-L1+)	10-Feb-2026
Adquey	Difamilast 1%	Acrotech / Otsuka	Atopic Dermatitis	12-Feb-2026
Filkri	Filgrastim-laha	Accord BioPharma	Neutropenia (Biosimilar to Neupogen)	17-Feb-2026
Bysanti	Milsaperidone	Vanda	Schizophrenia / Bipolar I	20-Feb-2026
Loargys	Pegzilarginase-nbln	Immedica	Arginase 1 Deficiency	23-Feb-2026
Desmoda	Desmopressin acetate	—	Central Diabetes Insipidus	25-Feb-2026

M&A Deals

Servier acquires Day One Biopharmaceuticals: $2.5 billion (Announced March 6, 2026). An all-cash deal expected to close Q2 2026, adding Day One's pediatric low-grade glioma program to Servier's rare oncology portfolio. Servier is foundation-governed rather than shareholder-driven, which makes this a notably long-term bet rather than a near-term commercial play. Source

GSK licenses linerixibat to Alfasigma: up to $690 million (Announced March 9, 2026). GSK out-licenses its cholestatic pruritus drug for primary biliary cholangitis to Italian pharma Alfasigma — $300M upfront and $100M on approval, with a PDUFA date of March 24. It's always interesting when a company licenses away an asset days before a decision. Watch this one for context after the 24th. Source

Clinical Trial Setbacks

Claseprubart (CIDP) — Dianthus Therapeutics: Interim responder analysis results from the Phase 3 CAPTIVATE trial in chronic inflammatory demyelinating polyneuropathy came in on March 9, 2026. The data were mixed enough to keep investors on edge, though the company still has a full Phase 3 readout ahead and substantial cash runway into 2028. Source

North American Enrollment — A Brewing Regulatory Problem: Worth flagging as a trend: FDA's ODAC recently voted 8–1 against the applicability of the STARGLO trial's results to the US population, in large part because less than 5% of patients enrolled were from the United States. Regulators are increasingly scrutinizing multinational datasets that lack meaningful US representation. This isn't one failure — it's a pattern that could create late-stage approval risk for sponsors who rely heavily on ex-US enrollment. A conversation the industry needs to have now, not at submission. Source

Macro: The NIH Funding Disruption Is Real and Getting Bigger

This deserves its own section because it's affecting our world directly. A new analysis published in JAMA Internal Medicine found that NIH grant terminations have disrupted 383 clinical trials — about 1 in 30 of all active NIH-funded studies — affecting over 74,000 enrolled patients and representing $1.81 billion in lost funding. Infectious disease trials were hit hardest (14.4% terminated), followed by prevention-focused and behavioral intervention studies. The Northeast and globally-sited trials bore disproportionate impact. Source — AJMC

As one researcher put it: "Clinical trials aren't light switches. You can't just flip them off without consequences." The human cost is immediate; the scientific cost — missed evidence, disrupted longitudinal data, broken patient trust — compounds over years. Sponsors running trials with NIH co-funding or academic partnerships need to be actively pressure-testing their continuity plans right now.

Trials to Watch in the Coming Weeks

A few high-stakes readouts are imminent:

Orforglipron (Eli Lilly): March PDUFA date for this once-daily oral GLP-1. If approved, the pricing decision will set the tone for the entire oral obesity drug market. Oral GLP-1s are expected to capture roughly 20% of an $80B+ category by 2030 — how Lilly prices this one matters for everyone downstream. Source
Linerixibat (Alfasigma, formerly GSK): PDUFA March 24. First-in-class IBAT inhibitor for cholestatic pruritus in primary biliary cholangitis. The GSK-to-Alfasigma licensing deal announced March 9 added some intrigue to what was already a closely watched decision.
Pelacarsen (Novartis/Ionis): Phase 3 Lp(a)HORIZON data expected H1 2026. At least one analyst has called this the "biggest biotech event of the entire year" — if successful, it could establish Lp(a) as a mainstream cardiovascular treatment target and open up an entirely new drug class. Source
Remternetug (Eli Lilly, Alzheimer's): Top-line Phase 3 TRAILRUNNER-ALZ 1 data expected H1 2026. Lilly's next anti-amyloid antibody after donanemab — the Alzheimer's pipeline pressure is real and building.

The Big Picture

Three themes dominate this period.

The NIH funding situation is a structural risk, not a one-off. Sponsors, CROs, and sites that relied on federal co-funding need to redesign for resilience — politically-driven trial terminations mid-stream are now a real operational scenario, not a theoretical one.

Ovarian cancer finally has an immunotherapy option. The Keytruda approval in platinum-resistant disease closes a long-standing gap. The fact that this is the first positive IO trial in the space after years of failures is worth appreciating — it took the right trial design, the right population selection, and a companion diagnostic to make it work.

M&A remains aggressive and well-funded. The Servier and GSK deals this period are consistent with what the broader industry is projecting: 20+ acquisitions over $1B in 2026, driven by the patent cliff bearing down on most of the top 12 pharma companies. Rare oncology and CNS assets continue to command the highest premiums. Source

Quick Links

Clinical Trials Dashboard: https://lebolger.github.io/Intellitrials/2026dashboard.html
M&A Tracker: lebolger.github.io/Intellitrials/docs/mnatracker.html
FDA Approvals: https://lebolger.github.io/Intellitrials/fda-approvals.html

Thursday, March 12, 2026

The Biggest Clinical Trial Results of 2026 (So Far)

Clinical trials in early 2026 have already delivered some major moments—record-breaking obesity drug results, promising rare-disease therapies, and a few painful late-stage failures. Below are the trial results that are actually moving medicine, markets, and the future of drug development.

The obesity drug race just escalated again

The biggest headline so far this year comes from Eli Lilly, whose triple-agonist drug retatrutide produced unprecedented weight-loss results in a late-stage trial.

Patients lost nearly 29% of body weight after 68 weeks, pushing drug-induced weight loss closer to what we normally see with bariatric surgery. Earlier studies published in The New England Journal of Medicine already hinted at this level of efficacy, and the newer Phase 3 data confirms that multi-hormone drugs may become the next generation of obesity therapies.

Source
https://www.nejm.org/doi/full/10.1056/NEJMoa2301972

Why it matters: obesity drugs are now projected to become a $100B global market this decade, according to McKinsey & Company.
https://www.mckinsey.com/industries/life-sciences/our-insights/the-obesity-market-could-reach-100-billion-by-2030

Kidney disease may finally get a major new therapy

Another major result came from Vertex Pharmaceuticals, which reported strong Phase 3 data for povetacicept in IgA nephropathy.

The trial showed a 52% reduction in proteinuria, one of the key markers used to track disease progression. Patients also experienced large reductions in pathogenic antibodies associated with kidney damage.

Source
https://www.reuters.com/business/healthcare-pharmaceuticals/vertexs-kidney-disease-drug-meets-main-goal-late-stage-trial-2026-03-09/

Why it matters: IgA nephropathy affects hundreds of thousands globally, and treatment options are still limited.

Duchenne muscular dystrophy therapy shows promising functional benefit

In rare disease research, Capricor Therapeutics reported encouraging results for its cell therapy deramiocel in Duchenne muscular dystrophy.

Trial data showed an 83% slowing in decline of functional tasks, suggesting the therapy could significantly delay disease progression.

Source
https://www.stocktitan.net/news/CAPR/capricor-therapeutics-reports-fourth-quarter-and-full-year-2025-zmo5hie061lg.html

An FDA decision is expected later in 2026.

Pulmonary fibrosis trial points to a new treatment approach

A pivotal trial evaluating inhaled treprostinil demonstrated improved lung function outcomes in idiopathic pulmonary fibrosis.

The study—reported in The New England Journal of Medicine—showed improved forced vital capacity and reduced disease progression compared with placebo.

Source
https://www.nejm.org

Why it matters: IPF is a devastating disease with limited therapeutic options.

A major breast-cancer trial disappointment

Not every big trial this year has succeeded.

A late-stage study of giredestrant, an oral estrogen-receptor degrader developed by Roche, failed to significantly improve progression-free survival in advanced breast cancer.

Source
https://www.wsj.com/health/pharma/roche-breast-cancer-treatment-falls-short-of-primary-goal-in-late-stage-study

The result is a setback for the oral SERD drug class, which had been expected to compete in a multibillion-dollar endocrine therapy market.

Quick snapshot of major trial readouts in 2026

Therapy	Company	Disease	Key result
Retatrutide	Eli Lilly	Obesity	~29% weight loss
Povetacicept	Vertex	IgA nephropathy	52% reduction in proteinuria
Deramiocel	Capricor	Duchenne muscular dystrophy	83% slower functional decline
Treprostinil (inhaled)	United Therapeutics	Pulmonary fibrosis	Improved lung function
Giredestrant	Roche	Breast cancer	Failed Phase 3 endpoint

The big trends emerging in 2026 trials

Three patterns are becoming clear.

Obesity drugs are entering a new era.
Multi-hormone therapies are now delivering results once thought impossible with medication alone.

Rare diseases remain a major source of innovation.
Many of the most meaningful advances this year are coming from small patient populations.

The risk of drug development remains brutal.

Even promising drugs can fail in late-stage trials, wiping out years of work and billions in market value.

Thursday, February 12, 2026

Clinical Trial News 12-Feb-2026

FDA Drug Approvals

Darzalex Faspro (daratumumab and hyaluronidase-fihj): Label expansion approved 27-Jan-2026 in combination with VRd for newly diagnosed multiple myeloma patients ineligible for transplant. Johnson & Johnson. FDA Link
Zycubo (copper histidinate): Approved 12-Jan-2026 as the first treatment for Menkes disease, a rare copper metabolism disorder. FDA Link
Fibryga (fibrinogen, human): Expanded 2-gram kit approved 07-Jan-2026 for acquired fibrinogen deficiency, designed for faster administration in critical bleeding. Octapharma. FDA Link
Cablivi (caplacizumab-yhdp): Pediatric expansion approved 05-Jan-2026 for children 12 years with acquired thrombotic thrombocytopenic purpura (aTTP). Sanofi. FDA Link
Generic Glatiramer Acetate: Approved 05-Jan-2026 as the first complex injectable generic for relapsing multiple sclerosis. ScinoPharm. FDA Link
ProlivRx: Approved Jan 2026 as the first at-home, physician-directed neuromodulation device for Major Depressive Disorder (MDD).

M&A Deals

GSK acquires RAPT Therapeutics: $2.2 billion (Announced Jan 20, 2026). Secures RAPT’s oral small molecules for inflammation and oncology, strengthening GSK's respiratory/immunology pipeline. Source
AbbVie & RemeGen Licensing: $5.6 billion total (Jan 12, 2026). AbbVie gains rights to a bispecific antibody for oncology, continuing its aggressive expansion in targeted therapies. Source
Lilly & Seamless Therapeutics: $1.12 billion (Jan 28, 2026). A strategic collaboration focused on modular gene editing for neurological disorders. Source
AstraZeneca & SanegeneBio: $1.7 billion (Jan 30, 2026). Licensing deal for an RNAi technology platform to address metabolic and cardiovascular indications. Source
BMS & Janux Therapeutics: $1.035 billion (Jan 2026). Licensing deal for tumor-activated bispecific antibodies targeting solid tumors. Source

Clinical Trial Setbacks

Bausch Health (rifaximin SSD): Phase 3 Red-C trials failed (Jan 23, 2026). The Xifaxan successor did not meet primary objectives for the prevention of hepatic encephalopathy in cirrhosis patients. Source
Milvexian (J&J/BMS): Phase 3 futility analysis (Feb 2026) led to the early termination of the ACS (Acute Coronary Syndrome) study, though other Phase 3 indications remain active. Source

Technological Breakthroughs

NIH "Digital Twin" of the Eye: In Feb 2026, the NIH unveiled a high-resolution 3D digital replica of retinal pigment epithelial cells, providing a new AI-driven modeling platform to accelerate AMD drug discovery. Source
AI-Driven IND Streamlining: Data from Parexel in early 2026 shows AI systems are now preparing IND (Investigational New Drug) submissions 50% faster, significantly cutting the time from "ready" to "regulatory review." Source

Market Insights

The "Obesity Platform" Era: Experts at the 2026 J.P. Morgan Healthcare Conference noted a shift from mere GLP-1 novelty to supply chain scale and multi-modal platforms (oral, weekly, and combination therapies) to capture the projected $200B market. Source
Patent Cliff Pressure: 2026 marks the beginning of the "cliff," with over 40% of Big Pharma revenue at risk of loss of exclusivity (LoE) by 2030, driving the current 15% surge in late-stage M&A. Source

Summary Table: Recent Major FDA Actions

Brand Name	Active Ingredient	Company	Indication	Approval Date
Darzalex Faspro	Daratumumab	J&J	Newly Diagnosed Multiple Myeloma	27-Jan-2026
Zycubo	Copper histidinate	N/A	Menkes Disease	12-Jan-2026
Fibryga (2g)	Fibrinogen	Octapharma	Acquired Fibrinogen Deficiency	07-Jan-2026
Cablivi	Caplacizumab	Sanofi	Pediatric aTTP	05-Jan-2026
N/A (Generic)	Glatiramer Acetate	ScinoPharm	Relapsing Multiple Sclerosis	05-Jan-2026
ProlivRx	Neuromodulation	ProlivRx	MDD (At-Home Device)	Jan-2026

Quick Links

Clinical Trials Dashboard: https://lebolger.github.io/Intellitrials/2026dashboard.html
M&A Tracker: https://lebolger.github.io/Intellitrials/docs/mnatracker.html
FDA Approvals: https://lebolger.github.io/Intellitrials/fda-approvals.html